# A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre

Source: https://onco.cc/trials/nct06018337/  
OnCo record `nct06018337` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc., active.

## Summary

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) is a phase 3 interventional study registered as NCT06018337 by DualityBio Inc., with 541 participants enrolled, started 2024-01-18. Conditions listed: Metastatic Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: DYNASTY-Breast02
- Tags: ctgov-ingest
- Registry id: NCT06018337
- Phase: 3
- Setting: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
- Sponsor: DualityBio Inc.
- Enrolled: 541

## Sources

- ClinicalTrials.gov NCT06018337: https://clinicaltrials.gov/study/NCT06018337

## Connected records

- cancers: [HER2-low and HER2-ultralow metastatic breast cancer](https://onco.cc/cancers/her2-low-metastatic-breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/)
- companies: [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06018337.json